Cost-Effectiveness of Preventive Strategies for Women with a BRCA1 or a BRCA2 Mutation
暂无分享,去创建一个
A. Neugut | D. Heitjan | J. Jacobson | J. Zivin | V. Grann | D. Hershman | Dawn Hershman | Kristin Anderson | Judith Jacobson | Daniel Heitjan | Joshua Zivin | Alfred Neugut | Victor Grann | K. Anderson
[1] P. Clement,et al. Endometrioid Carcinoma of the Uterine Corpus: A Review of Its Pathology With Emphasis on Recent Advances and Problematic Aspects , 2002, Advances in anatomic pathology.
[2] S. Pauker,et al. The Markov Process in Medical Prognosis , 1983, Medical decision making : an international journal of the Society for Medical Decision Making.
[3] E. Thomson,et al. Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer: I. Hereditary Nonpolyposis Colon Cancer , 1997 .
[4] J. Klijn,et al. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] D. Berry,et al. Testing for the BRCA1 and BRCA2 Breast-Ovarian Cancer Susceptibility Genes , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[6] J. Lubitz,et al. Trends in Medicare payments in the last year of life. , 1993, The New England journal of medicine.
[7] E. Swisher. Prophylactic surgery and other strategies for reducing the risk of familial ovarian cancer , 2003, Current treatment options in oncology.
[8] P. Clement,et al. Endometrioid Carcinoma of the Uterine Corpus: A Review of Its Pathology With Emphasis on Recent Advances and Problematic Aspects , 2002, Advances in anatomic pathology.
[9] K. Kinzler,et al. The Genetic Basis of Human Cancer , 1997 .
[10] A S Detsky,et al. Screening for breast cancer: time, travel, and out-of-pocket expenses. , 1999, Journal of the National Cancer Institute.
[11] E. Berns,et al. Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] B. Ponder,et al. Oral Contraceptives and the Risk of Hereditary Ovarian Cancer , 1998 .
[13] O. Olopade,et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. , 1999, Journal of the National Cancer Institute.
[14] D J Schaid,et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. , 1999, The New England journal of medicine.
[15] Robert N. Hughes,et al. Cancer: Principles and Practice of Oncology , 2005 .
[16] B. Weber,et al. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. , 2004, Journal of Clinical Oncology.
[17] P. Chappuis,et al. The influence of familial and hereditary factors on the prognosis of breast cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] T. Walsh,et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. , 2001, JAMA.
[19] J. Satagopan,et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Neugut,et al. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] L. Kessler,et al. Medicare Payments from Diagnosis to Death for Elderly Cancer Patients by Stage at Diagnosis , 1995, Medical care.
[22] T. Rebbeck,et al. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] R. Lawrenson,et al. Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany. , 1998, American journal of obstetrics and gynecology.
[24] B. Fisher. National Surgical Adjuvant Breast and Bowel Project breast cancer prevention trial: a reflective commentary. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] A. Neugut,et al. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] B. Bernhardt,et al. What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. King,et al. Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.
[28] A. Neugut,et al. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] J. Klijn,et al. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J D Habbema,et al. Endoscopic colorectal cancer screening: a cost-saving analysis. , 2000, Journal of the National Cancer Institute.
[31] Ruth Etzioni,et al. Estimating Health Care Costs Related to Cancer Treatment From SEER-Medicare Data , 2002, Medical care.
[32] A. Whittemore,et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations , 2004, British Journal of Cancer.
[33] M. Gold. Cost-effectiveness in health and medicine , 2016 .
[34] B. Ponder,et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. , 1998, The New England journal of medicine.
[35] H. Iwase,et al. [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.
[36] H. Linden,et al. The cost of adjuvant chemotherapy in patients with early‐stage breast carcinoma , 2005, Cancer.
[37] Sunil R Lakhani,et al. The pathology of familial breast cancer: Immunohistochemistry and molecular analysis , 1999, Breast Cancer Research.
[38] L. Kessler,et al. Potential for Cancer Related Health Services Research Using a Linked Medicare‐Tumor Registry Database , 1993, Medical care.
[39] A. Neugut,et al. The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations. , 1999, The cancer journal from Scientific American.
[40] T. Powles,et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.
[41] P. Boyle,et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women , 1998, The Lancet.
[42] T. Sellers,et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. , 2001, Journal of the National Cancer Institute.
[43] K M Kuntz,et al. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. , 1997, The New England journal of medicine.
[44] P. Hartge,et al. Breast cancer risks for BRCA1/2 carriers. , 2004, Science.
[45] P. Devilee,et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation , 2000, The Lancet.
[46] W. Lawrence,et al. Cost of genetic counseling and testing for BRCA1 and BRCA2 breast cancer susceptibility mutations. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[47] M. Weinstein,et al. Cost-effectiveness of hormone replacement therapy in the menopause. , 1983, Obstetrical & gynecological survey.
[48] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[49] P. Schwartz. Nongenetic screening of ovarian malignancies. , 2001, Obstetrics and gynecology clinics of North America.
[50] E. Bass,et al. Preference Values for Visual States in Patients Planning to Undergo Cataract Surgery , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.
[51] Susan L Neuhausen,et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.
[52] E. Thomson,et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. , 1997, JAMA.
[53] C. Somkin,et al. Cost of Care for Cancer in a Health Maintenance Organization , 1997, Health care financing review.
[54] J. Satagopan,et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.
[55] Taylor Murray,et al. Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.
[56] P. Stalmeier,et al. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] M Baum,et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial , 2002, The Lancet.
[58] C K Redmond,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.
[59] P. Chappuis,et al. Re: Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. , 2001, Journal of the National Cancer Institute.
[60] Z. Calay,et al. Endometrial mixed Müllerian tumor with heterologous elements following tamoxifen therapy for breast cancer: a case report and literature review. , 2002, European journal of obstetrics, gynecology, and reproductive biology.
[61] C Milligan,et al. Screening for cervical cancer. , 1975, The American journal of nursing.
[62] J. Klijn,et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 , 1998, The Lancet.
[63] A. Whittemore,et al. Oral Contraceptive Use and Risk of Early-Onset Breast Cancer in Carriers and Noncarriers of BRCA1 and BRCA2 Mutations , 2005, Cancer Epidemiology Biomarkers & Prevention.
[64] J. Klijn,et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.
[65] J. Bryant,et al. Association of tamoxifen and uterine sarcoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] K. Heimdal,et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study , 2000, The Lancet.
[67] T. Schacker,et al. Annals of Internal Medicine , 1992 .
[68] K Holli,et al. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. , 2000, Journal of the National Cancer Institute.
[69] D. Easton,et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies , 2005, Journal of Medical Genetics.
[70] A. Alavi,et al. The clinical course of pulmonary embolism. , 1992, The New England journal of medicine.
[71] J. Satagopan,et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment , 2003, Breast Cancer Research.